CJ Biomaterials Names Harry Jang as New CEO

CJ Biomaterials, a division of South Korea-based CJ CheilJedang and a primary producer of PHA (polyhydroxyalkanoate) bioplastics, has named Harry Jang as its new CEO. As the head of CJ Biomaterials, Jang will oversee the company’s strategic direction, drive innovation in sustainable materials and spearhead efforts to expand market presence and partnerships in the global bioplastics industry.

Jang joined CJ CheilJedang in 1995 and has taken over roles of increasing responsibility at CJ businesses around the world, working in Korea, Brazil, Vietnam, Germany and, most recently, the United States. From 2020 to February 2024, he served as the CEO of CJ Bio America, leading global sales and operations for the amino acid portfolio. During his tenure, Jang helped CJ Bio America to grow its business, including an expansion of operations at its Ft. Dodge, Iowa, production facility.

Says Jang, "Having had the opportunity to work across diverse markets worldwide, I understand the complexities and opportunities inherent in global business, and I am excited to leverage my international insights to continue to elevate CJ Biomaterials. CJ Biomaterials has a talented team and together we will navigate global markets with agility, innovation and a commitment to sustainability to drive positive change in the bioplastics industry."